BR100 Increased By (0.46%)
BR30 Increased By (0.64%)
KSE100 Increased By (0.41%)
KSE30 Increased By (0.52%)
BECO 5.72 Decreased By ▼ -0.01 (-0.17%)
BML 57.16 Decreased By ▼ -0.14 (-0.24%)
BOP 36.85 Increased By ▲ 0.08 (0.22%)
CNERGY 8.49 Increased By ▲ 0.10 (1.19%)
DCL 11.99 Decreased By ▼ -0.05 (-0.42%)
FCCL 58.40 Decreased By ▼ -0.21 (-0.36%)
FCSC 5.15 Increased By ▲ 0.14 (2.79%)
FFL 18.32 Increased By ▲ 0.38 (2.12%)
FNEL 1.26 No Change ▼ 0.00 (0%)
HUMNL 11.50 Increased By ▲ 0.08 (0.7%)
KEL 8.36 Increased By ▲ 0.07 (0.84%)
KOSM 6.62 No Change ▼ 0.00 (0%)
MLCF 107.34 Decreased By ▼ -0.95 (-0.88%)
NBP 208.29 Increased By ▲ 2.25 (1.09%)
PACE 11.35 Increased By ▲ 0.18 (1.61%)
PAEL 45.45 Increased By ▲ 0.10 (0.22%)
PIAHCLA 30.45 Decreased By ▼ -0.32 (-1.04%)
PIBTL 18.89 Decreased By ▼ -0.17 (-0.89%)
PPL 248.90 Increased By ▲ 2.95 (1.2%)
PRL 36.72 Increased By ▲ 0.64 (1.77%)
PTC 74.70 Increased By ▲ 2.34 (3.23%)
SEARL 96.26 Decreased By ▼ -0.41 (-0.42%)
SSGC 31.50 Decreased By ▼ -0.17 (-0.54%)
TELE 9.25 Decreased By ▼ -0.02 (-0.22%)
THCCL 68.70 Increased By ▲ 0.89 (1.31%)
TPLP 11.50 Increased By ▲ 0.27 (2.4%)
TREET 25.80 Decreased By ▼ -0.09 (-0.35%)
TRG 68.10 Increased By ▲ 0.26 (0.38%)
WAVES 11.30 Increased By ▲ 0.32 (2.91%)
WTL 1.28 No Change ▼ 0.00 (0%)
Business & Finance

AstraZeneca resumes COVID-19 vaccine trials in South Africa, health dept says

  • The move, confirmed to Reuters by director of affordable medicines in the health department, Khadija Jamaloodien, comes after the British drugmaker.
  • Tests remain on hold in the United States pending an investigation and the Serum Institute of India.
Published September 15, 2020 Updated September 15, 2020 08:23pm
By

JOHANNESBURG: AstraZeneca has resumed COVID-19 vaccine trials in South Africa, more than a week after tests were paused due to serious side effects in a participant in Britain, an official at the country's Department of Health told Reuters on Tuesday.

The move, confirmed to Reuters by director of affordable medicines in the health department, Khadija Jamaloodien, comes after the British drugmaker on Saturday got the go-ahead to restart trials in the UK, prompting Brazil to follow suit.

Tests remain on hold in the United States pending an investigation and the Serum Institute of India said it would restart its trials once it had permission from the Drugs Controller General of India.

Comments

Comments are closed for this article.